The Application For Marketing Authorization Of The Trivalent HPV Vaccine Of Kangle Guard Has Been Accepted
April 27, 2025
Source: drugdu
76
On April 24, according to Kangle GuardAccording to the news, its holding subsidiary, Kangleweishi (Kunming) Biotechnology Co., Ltd., received the "Acceptance Notice" (Acceptance No.: CXSS2500048) issued by the Center for Drug Evaluation (CDE) of the State Drug Administration. The company's independently developed recombinant trivalent human papillomavirus (16/18/58) vaccine (Escherichia coli) (referred to as "trivalent HPV vaccine") marketing authorization application was accepted by CDE. The trivalent HPV vaccine independently developed by Kangleweishi is mainly used to prevent persistent infection of HPV 16/18/58 and the resulting precancerous lesions and cervical cancer and other diseases.
https://finance.eastmoney.com/a/202504243387405326.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- How Can Pharmaceutical Exporters Secure Their First Overseas Distributor?— A Practical Guide from Sourcing to Evaluation and Negotiation May 16, 2025
- Trump signs executive order to lower prescription drug prices, expected to have limited short-term impact May 16, 2025
- Huasen Pharmaceutical plans to hold a controlling stake in Aorui Pharmaceutical to promote the development of innovative drugs in the fields of oncology and immunotherapy May 16, 2025
- New Drug Combos Could Cut Heart Failure Mortality by 60% May 16, 2025
- GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug May 16, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
